Sudeep Pharma Limited has informed the Exchange about Transcript

Sudeep Pharma reported strong FY26 results with revenue of INR642.3 crores (up 28% YoY) and PAT of INR174.3 crores. However, EBITDA margin declined to 34.6% from 37.8% in FY25 due to higher raw material costs, one-time expenses, and significant investments in building teams for North America and Europe. Specialty Ingredients emerged as the fastest-growing segment with 62% growth to INR280 crores, now contributing 44% of revenues. Management guided that margins should recover to historical levels of 37-38% over the coming quarters as one-time costs normalize. The company has 42 customers in pipeline for its battery materials business with 6 already at commercial validation stage and ~700 MT orders received. The new greenfield facility is now operational and customer qualification process is underway.